465 State Route 17
Ramsey, NJ 07446
United States
201 478 5552
https://www.admabiologics.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 624
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Adam S. Grossman | Co-Founder, President, CEO & Director | 1,52M | N/D | 1977 |
Dr. Jerrold B. Grossman D.P.S., Ph.D. | Co-Founder & Vice Chairman of the Board | 80k | N/D | 1948 |
Mr. Brian Lenz CPA | Executive VP, CFO & GM of ADMA BioCenters | 1,08M | N/D | 1972 |
Ms. Kaitlin Kestenberg | Senior Vice President of Compliance & Project Operations | N/D | N/D | N/D |
Mr. Drew Pantello | Vice President of Marketing & Corporate Development | N/D | N/D | N/D |
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
L'ISS Governance QualityScore di ADMA Biologics, Inc. al 1 marzo 2024 è 7. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 7.